JQEZ5
Tocris Bioscience, part of Bio-Techne | Catalog # 6153
Potent and selective SAM-competitive EZH2 inhibitor
Key Product Details
Description
Potent and selective SAM-competitive EZH2 inhibitor
Product Description
JQEZ5 is a potent and selective SAM-competitive EZH2 lysine methyltransferase inhibitor (IC50 = 11 nM). Selectively binds EZH2 over a panel of 22 methyltransferases. Reduces global level of the PRC2-associated mark H3K27me3 in K562 cells. Suppresses cell growth in CML cells. Inhibits colony formation of primary human CD34+ CML stem/ progenitor cells. Antitumor effects in vivo.Licensing Information
Sold under license from Dana-Farber Cancer Institute.Product Specifications
Molecular Weight
542.69
Formula
C30H38N8O2
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
N-[(1,2-Dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
CAS Number
1913252-04-6
PubChem ID
121322599
InChI Key
LQTWDAYNGMMHLV-UHFFFAOYSA-N
SMILES
CN(CC1)CCN1C2=CC=C(C3=NC(N(C(C)C)N=C4)=C4C(C(NCC5=C(CCC)C=C(C)NC5=O)=O)=C3)C=N2
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 10.85 | 20 |
Preparing Stock Solutions
for JQEZ5
The following data is based on the product molecular weight 542.69
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.2 mM | 9.21 mL | 46.07 mL | 92.13 mL |
| 1 mM | 1.84 mL | 9.21 mL | 18.43 mL |
| 2 mM | 0.92 mL | 4.61 mL | 9.21 mL |
| 10 mM | 0.18 mL | 0.92 mL | 1.84 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Frankel Developing EZH2-targeted therapy for lung cancer. Cancer Discov. 2016 PMID: 27587466
- Zhang Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov. 2016 PMID: 27312177
- Xie Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2. Send to 2016 PMID: 27630126
Product Specific Notices for JQEZ5
For research use only
Loading...
Loading...